Clinical trials: Lymphocytic Bronchiolitis
Lymphoma, Non-Hodgkin's Lymphoma
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT01149668
- Testing
- PCI-24781
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Pharmacyclics LLC.
Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of ofatumumab monotherapy in Japanese follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL) patients.
- Trial name
- NCT00742144
- Testing
- ofatumumab
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Lymphocytic Leukemia, Chronic
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.
- Trial name
- NCT00431873
- Testing
- MGCD0103
- Where
- 13 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Mirati Therapeutics Inc.
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL)
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin…
- Conditions
- Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL)
- Trial name
- NCT01994382
- Testing
- Cerdulatinib, Rituximab
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, CLL
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
- Trial name
- NCT00021749
- Testing
- Oblimerson sodium, G3139
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genta Incorporated
Multiple Myeloma, Chronic Lymphocytic Leukaemia
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
The aim of this study is to determine the safety, tolerability and dose-limiting toxicities of KW-2478 and to determine the Maximum Tolerated Dose and recommended Phase II dose for patients with relapsed/refractory MM, CLL or…
- Conditions
- Multiple Myeloma, Chronic Lymphocytic Leukaemia, B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT00457782
- Testing
- KW-2478
- Where
- 6 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease.
- Trial name
- NCT01680991
- Testing
- Obinutuzumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients…
- Trial name
- RESONATE™ (NCT01578707)
- Testing
- ofatumumab, ibrutinib
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 391 people
- Sponsor
- Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
The purpose of this study is to determine whether duvortuxizumab and ibrutinib can be combined safely and to establish the maximum tolerated dose (MTD) in Part 1 and the recommended Phase 2 dose (RP2D) and to further explore the…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
- Trial name
- NCT02743546
- Testing
- Duvortuxizumab, Ibrutinib
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments.
- Trial name
- NCT00078234
- Testing
- Oblimersen-rituximab-fludarabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genta Incorporated
Myelodysplastic Syndromes, Leukemia Myeloid Acute
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless of whether they are highly…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leuklemia, Lymphocytic, Chronic
- Trial name
- GAH (NCT02164071)
- Testing
- Geriatric Assessment of Health Status Scale administration
- Where
- 22 sites in Spain
- Volunteers
- 363 people
- Sponsor
- Celgene
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients with late-stage solid tumors or hematologic malignancies.
- Trial name
- NCT00825487
- Testing
- ARQ 621
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Long-term Extension Study of PCI-32765 (Ibrutinib)
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- CAN3001 (NCT01804686)
- Testing
- Ibrutinib
- Where
- 175 sites in United States, Argentina and 28 more
- Volunteers
- 539 people
- Sponsor
- Janssen Research & Development, LLC
Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT02461316
- Testing
- No intervention
- Where
- 3 sites in Serbia
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
- Trial name
- NCT01991184
- Testing
- GDC-0853
- Where
- 10 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
This is a Phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATH, MabCampath) as therapy for patients with relapsed or refractory B-CLL who…
- Trial name
- NCT00328198
- Testing
- Alemtuzumab
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Genzyme, a Sanofi Company